SNSW(SH:688117) Zheng Quan Zhi Xing·2025-08-22 16:24Core Viewpoint - The major shareholders and some directors and senior management of Chengdu Saintno Biological Technology Co., Ltd. have announced a share reduction plan due to personal funding needs and other financial considerations [1][2]. Shareholding Information - Sichuan Development Securities Investment Fund Management Co., Ltd. holds 11,407,021 shares, accounting for 7.2478% of the total share capital, with 431,021 shares acquired through centralized bidding [1][4]. - Vice General Manager Lu Changliang holds 386,316 shares, representing 0.2455% of the total share capital, with part of the shares obtained from the 2023 restricted stock incentive plan [1][5]. - Director and Vice General Manager Wang Xiaoli holds 2,298,786 shares, accounting for 1.4606% of the total share capital, with shares obtained before the IPO and from the 2023 incentive plan [1][5]. Reduction Plan Details - Sichuan Development plans to reduce up to 4,721,578 shares, not exceeding 3% of the total share capital, through centralized bidding and block trading [2][7]. - Lu Changliang plans to reduce up to 96,579 shares (0.0614%) and Wang Xiaoli plans to reduce up to 574,696 shares (0.3652%) within the same timeframe [2][7]. - The reduction period for all parties is set from September 15, 2025, to December 14, 2025 [7]. Previous Reduction Activities - Sichuan Development has previously reduced 1,128,207 shares (1.01%) between August 15, 2024, and August 26, 2024, at prices ranging from 24.7903 to 26.8438 yuan per share [6]. Compliance and Commitments - The shareholders have committed to adhere to relevant regulations regarding share reductions and have no current restrictions preventing them from executing the planned reductions [8][9].